Patents by Inventor Hiroki Tanisaka
Hiroki Tanisaka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11382927Abstract: An object of the present invention is to provide a liquid medicinal preparation which does not generate precipitates and is suitable for mass production. According to the present invention, provided is a liquid medicinal preparation that contains 1-(2-deoxy-2-fluoro-4-thio-?-D-arabinofuranosyl)cytosine or a salt thereof, a polyhydric alcohol having a molecular weight of 100 or less, and water. The polyhydric alcohol is preferably glycerin, propylene glycol, or butanediol.Type: GrantFiled: August 28, 2018Date of Patent: July 12, 2022Assignee: FUJIFILM CorporationInventors: Hiroki Tanisaka, Tatsuya Murakami
-
Patent number: 10772895Abstract: Provided is a pharmaceutical composition which contains fulvestrant in an amount of equal to or greater than 8% by mass with respect to the entire mass of the pharmaceutical composition, an aqueous solvent satisfying (1) to (4), and a pharmaceutically acceptable nonaqueous carrier satisfying (A) and (B). (1) Ethanol is contained in an amount of equal to or greater than 8% by mass with respect to the entire mass of the pharmaceutical composition. (2) At least one kind of polyhydric alcohol selected from propylene glycol or 1,3-butylene glycol is contained in an amount of equal to or greater than 3% by mass with respect to the entire mass of the pharmaceutical composition. (3) A content of benzyl alcohol is less than 5% by mass with respect to the entire mass of the pharmaceutical composition. (4) A content of the aqueous solvent is 15% to 50% by mass with respect to the entire mass of the pharmaceutical composition.Type: GrantFiled: September 20, 2018Date of Patent: September 15, 2020Assignee: FUJIFILM CORPORATIONInventors: Hiroki Tanisaka, Kyoko Senga, Shuhei Osaka
-
Patent number: 10668083Abstract: Provided is a pharmaceutical composition which contains fulvestrant in an amount of 4.5% by mass to 10.0% by mass with respect to the entire mass of the pharmaceutical composition, at least one kind of polyhydric alcohol selected from propylene glycol or 1,3-butylene glycol in an amount of 8% by mass to 23% by mass with respect to the entire mass of the pharmaceutical composition, benzyl alcohol in an amount of 5% by mass to 24% by mass with respect to the entire mass of the pharmaceutical composition, benzyl benzoate in an amount of 8% by mass to 19% by mass with respect to the entire mass of the pharmaceutical composition, and castor oil, and in which a content of ethanol is less than 1% by mass with respect to the entire mass of the pharmaceutical composition, and a content of benzoic acid is less than 1% by mass with respect to the entire mass of the pharmaceutical composition.Type: GrantFiled: November 5, 2018Date of Patent: June 2, 2020Assignee: FUJIFILM CORPORATIONInventors: Hiroki Tanisaka, Kyoko Senga
-
Publication number: 20190070195Abstract: Provided is a pharmaceutical composition which contains fulvestrant in an amount of 4.5% by mass to 10.0% by mass with respect to the entire mass of the pharmaceutical composition, at least one kind of polyhydric alcohol selected from propylene glycol or 1,3-butylene glycol in an amount of 8% by mass to 23% by mass with respect to the entire mass of the pharmaceutical composition, benzyl alcohol in an amount of 5% by mass to 24% by mass with respect to the entire mass of the pharmaceutical composition, benzyl benzoate in an amount of 8% by mass to 19% by mass with respect to the entire mass of the pharmaceutical composition, and castor oil, and in which a content of ethanol is less than 1% by mass with respect to the entire mass of the pharmaceutical composition, and a content of benzoic acid is less than 1% by mass with respect to the entire mass of the pharmaceutical composition.Type: ApplicationFiled: November 5, 2018Publication date: March 7, 2019Inventors: Hiroki TANISAKA, Kyoko SENGA
-
Publication number: 20190022108Abstract: Provided is a pharmaceutical composition which contains fulvestrant in an amount of equal to or greater than 8% by mass with respect to the entire mass of the pharmaceutical composition, an aqueous solvent satisfying (1) to (4), and a pharmaceutically acceptable nonaqueous carrier satisfying (A) and (B). (1) Ethanol is contained in an amount of equal to or greater than 8% by mass with respect to the entire mass of the pharmaceutical composition. (2) At least one kind of polyhydric alcohol selected from propylene glycol or 1,3-butylene glycol is contained in an amount of equal to or greater than 3% by mass with respect to the entire mass of the pharmaceutical composition. (3) A content of benzyl alcohol is less than 5% by mass with respect to the entire mass of the pharmaceutical composition. (4) A content of the aqueous solvent is 15% to 50% by mass with respect to the entire mass of the pharmaceutical composition.Type: ApplicationFiled: September 20, 2018Publication date: January 24, 2019Inventors: Hiroki TANISAKA, Kyoko SENGA, Shuhei OSAKA
-
Publication number: 20180360865Abstract: An object of the present invention is to provide a liquid medicinal preparation which does not generate precipitates and is suitable for mass production. According to the present invention, provided is a liquid medicinal preparation that contains 1-(2-deoxy-2-fluoro-4-thio-?-D-arabinothranosyl)cytosine or a salt thereof, a polyhydric alcohol having a molecular weight of 100 or less, and water. The polyhydric alcohol is preferably glycerin, propylene glycol, or butanediol.Type: ApplicationFiled: August 28, 2018Publication date: December 20, 2018Applicant: FUJIFILM CorporationInventors: Hiroki TANISAKA, Tatsuya MURAKAMI
-
Publication number: 20140023718Abstract: There is provided a fat emulsion which has a pH of 4.5 to 6.0 and includes a prostaglandin compound, an oil ingredient, a lecithin, the content of which is 0.15 times or more by mass the content of the oil ingredient, a water-soluble acid having a pKa of 4.0 to 6.0 and having a dissociable group or a salt thereof, and water; and a fat emulsion which includes a prostaglandin compound, an oil ingredient, a lecithin, the content of which is 500 to 5,000 times by mass the content of the prostaglandin compound and is 0.5 to 10 times by mass the content of the oil ingredient, and water, and in which the content of a higher fatty acid is 0.06 times or less by mass the content of the lecithin.Type: ApplicationFiled: September 27, 2013Publication date: January 23, 2014Applicant: FUJIFILM CorporationInventors: Shigetomo TSUJIHATA, Hiroki TANISAKA, Kozo NAGATA, Yasuyuki IZUMI
-
Publication number: 20110275592Abstract: The invention provides an emulsion composition obtained by mixing an oil phase containing a carotenoid having a melting point of 100° C. or more as detected when it is contained in an oil; and an aqueous phase containing a polyglycerol fatty acid ester and a nonionic emulsifier different from the polyglycerol fatty acid ester, wherein a weight ratio (A)/(B) of an amount (A) of the polyglycerol fatty acid ester to an amount (B) of the nonionic emulsifier different from the polyglycerol fatty acid ester is in the range of 2.5 to 10, and a particle diameter of dispersed particles that contain the carotenoid is 200 nm or less.Type: ApplicationFiled: January 5, 2010Publication date: November 10, 2011Applicant: FUJIFILM CORPORATIONInventor: Hiroki Tanisaka